CPhI Online

- Biopharma News

Novasep to develop and manufacture Handl Therapeutics' gene therapy product

3 Nov 2020

The CDMO will supply drug substance and drug product to support Handl Therapeutics’ preclinical and clinical studies.

Novasep, a supplier of services and technologies for the life sciences industry, and Handl Therapeutics, gene therapy company, have signed a development and manufacturing agreement regarding an adeno associated virus-(AAV) based gene therapy drug candidate for the treatment of neurodegenerative diseases.

Handl Therapeutics is developing multiple therapeutic AAV-based programs in collaboration with the Katholieke Universiteit Leuven (Belgium), the Center for Applied Medical Research of the University of Navarra (Spain), and with the Biomedical Neuroscience Institute of the University of Chile. The company is currently conducting IND- (investigational new drug) enabling preclinical studies.

Under the terms of the agreement, Novasep will develop and manufacture AAV vectors designed for these programs and will supply drug substance and drug product to support Handl Therapeutics’ preclinical and clinical studies.

As part of its growth strategy Rise-2, Novasep recently unveiled a new facility, Senrise-IV - the company's flagship for the commercial production of viral vectors - which was completed last year with Senefill - a new Fill & Finish clinical and commercial facility for aseptic operations. Both facilities are located in Seneffe, Belgium.

"This new project is another step for Novasep to deliver its Rise-2 growth strategy, and shows our commitment to continue delivering customers' solution expanding our biopharmaceuticals franchise” said Michel Spagnol, Chairman & CEO of Novasep Group.

Read More

Related Content